GLP-1 weight loss timelines: what 22-year-olds on TikTok aren't being told

What did @presley_smithhh actually say?

Presley kept it simple and honest. She shared her starting stats, 22 years old, 5'7", 248 pounds, called this her "week one" on what the hashtags confirm is an Ozempic journey, and said she's posting publicly to hold herself accountable. No wild claims about the drug. No promises of specific numbers. Just a starting line.

That matters, because a lot of GLP-1 content on TikTok leads with transformation promises or miracle framing. Presley did neither. Her most pointed statement was "that is a lot I know, but that's what we're trying to do, we're trying to change." That's a goal, not a medical claim. The video is essentially a before photo with audio, and that's fine. There's nothing here to debunk medically, which is actually somewhat rare for the #ozempictiktok corner of the platform.

Does the science back this up?

The implicit premise, that a 22-year-old at 248 pounds and 5'7" can use a GLP-1 medication to lose meaningful weight, is well-supported by the clinical literature. At that height and weight, Presley's BMI sits around 38.9, which falls in the class II obesity range, the population that GLP-1 trials were largely built on.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that adults on semaglutide 2.4mg lost an average of 14.9% of body weight over 68 weeks versus 2.4% on placebo. A 2023 subgroup analysis from the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine) found tirzepatide produced up to 20.9% body weight reduction in people with obesity but without diabetes. Neither trial specifically isolated 22-year-olds, but younger adults with higher baseline weights tend to see strong responses. The biology here is real. GLP-1 receptors slow gastric emptying and signal satiety to the hypothalamus. This is not a placebo effect.

What did they get wrong, or right?

Presley got the framing right, and that is worth saying plainly. She did not claim Ozempic "melts fat" or promise a specific outcome. She did not tell her 41,000 viewers what dose she was on or suggest they do the same. That restraint is more responsible than a significant chunk of GLP-1 content currently circulating on TikTok.

One thing she glossed over, not wrongly exactly, but incompletely, is that week one is often the hardest week for side effects. Nausea, fatigue, and GI distress are reported by roughly 44% of semaglutide users in the early titration phase (Davies et al., 2021, Diabetes Care). If Presley felt fine at week one, that may not hold at higher doses. Viewers starting their own journeys and expecting smooth sailing from day one could be blindsided. She also didn't mention that results vary substantially based on dose, adherence, and diet. That's not misinformation. It's just an incomplete picture, which is normal for a 60-second intro video.

What should you actually know?

If you're 22, in a similar weight range, and considering a GLP-1 medication, here is what the research actually says. First, you likely qualify under standard prescribing criteria, a BMI of 30 or higher, or 27 with a weight-related condition. Second, these medications require a real prescriber and ongoing monitoring. They are not supplements. Third, compounded semaglutide and brand-name Wegovy are not the same product and should not be treated as interchangeable. The FDA has flagged this repeatedly.

Fourth, the dropout rate in GLP-1 trials is not trivial. A 2022 analysis in Obesity found that real-world discontinuation rates at 12 months exceeded 60% in some populations. The people who stay on the medication and pair it with behavioral changes see the best outcomes. Presley's instinct to post publicly for accountability is consistent with what behavioral science shows about commitment devices. Research by Ariely and Wertenbroch (2002, Psychological Science) found that self-imposed public accountability improves follow-through. That's not nothing.

The bottom line

This video is a personal starting point, not a medical tutorial, and it shouldn't be judged as one. Presley made no false claims, recommended no doses, and sold nothing. The actual science behind GLP-1 use in younger adults with class II obesity is solid. What viewers need to watch for as this series continues is whether future videos drift into dosing advice, product recommendations, or before-and-after framing that obscures the full picture of how these medications actually work over time.